Literature DB >> 1649272

Response of low-passage human malignant gliomas in vitro to stimulation and selective inhibition of growth factor-mediated pathways.

I F Pollack1, M S Randall, M P Kristofik, R H Kelly, R G Selker, F T Vertosick.   

Abstract

The proliferation of many nonglial tumors in vitro depends on the presence of nanomolar concentrations of one or more growth factors. To define the growth factor requirements of malignant glial tumors, the authors examined the response properties of four low-passage human malignant glioma lines to the following mitogens: epidermal growth factor (EGF), acidic and basic fibroblast growth factors (FGF's), insulin-like growth factor I (IGF-I), nerve growth factor (NGF), platelet-derived growth factor (PDGF), 12-O-tetradecanoyl-13-phorbol acetate (TPA), and serum. Each of the tumors showed increased deoxyribonucleic acid (DNA) synthesis (assessed by acid-precipitable [3H]-thymidine incorporation) in response to PDGF with a maximum effect at 50 ng/ml. Three tumors responded to EGF, three to IGF-I, two to acidic FGF, two to basic FGF, and two to TPA with maximum effects at 10, 50, 1, 1, and 10 ng/ml, respectively. None of the tumors responded to NGF. In the responsive tumors, optimum concentrations of EGF, IGF, TPA, acidic FGF, and basic FGF induced, at most, a two- to fourfold increase in [3H]-thymidine incorporation, which was only 30% to 50% of the response seen in 10% serum. In contrast, PDGF increased DNA synthesis eight- to 10-fold, equaling the effect of 10% serum. Measurements of cell proliferation also demonstrated a significant response to PDGF in each of the tumors. Appropriate concentrations of an anti-PDGF neutralizing antibody inhibited baseline DNA synthesis and proliferation in the absence of added growth factors, suggesting the possible role of PDGF in autocrine stimulation of these cells. However, this antibody produced only slight inhibition of serum-induced mitogenesis. Trapidil, an agent reported to inhibit the effects of PDGF, and polymyxin B, an inhibitor of protein kinase C, strongly inhibited baseline as well as PDGF- and serum-induced mitogenesis. It is concluded that, in the malignant gliomas studied, PDGF may be acting as a dominant mitogen to enhance DNA synthesis, and may function in autocrine stimulation. However, other factors contained in serum can also contribute to cell division.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1649272     DOI: 10.3171/jns.1991.75.2.0284

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  23 in total

1.  Sensitivity of human glioma U-373MG cells to radiation and the protein kinase C inhibitor, calphostin C.

Authors:  M Acevedo-Duncan; J Pearlman; B Zachariah
Journal:  Cell Prolif       Date:  2001-02       Impact factor: 6.831

2.  Protein kinase C inhibition by UCN-01 induces apoptosis in human glioma cells in a time-dependent fashion.

Authors:  M Bredel; I F Pollack; J M Freund; J Rusnak; J S Lazo
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

3.  Growth retardation in glioma cells cocultured with cells overexpressing a gap junction protein.

Authors:  D Zhu; G M Kidder; S Caveney; C C Naus
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

4.  Transforming growth factor beta as a potential tumor progression factor among hyperdiploid glioblastoma cultures: evidence for the role of platelet-derived growth factor.

Authors:  M T Jennings; C E Hart; P A Commers; J A Whitlock; D Martincic; R J Maciunas; P L Moots; T M Shehab
Journal:  J Neurooncol       Date:  1997-02       Impact factor: 4.130

5.  Low Concentration Microenvironments Enhance the Migration of Neonatal Cells of Glial Lineage.

Authors:  Richard A Able; Celestin Ngnabeuye; Cade Beck; Eric C Holland; Maribel Vazquez
Journal:  Cell Mol Bioeng       Date:  2012-06       Impact factor: 2.321

6.  A comparison of the relative chemosensitivity of human gliomas to tamoxifen and n-desmethyltamoxifen in vitro.

Authors:  F T Vertosick; R G Selker; M S Randall; M P Kristofik; T Rehn
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 7.  Therapeutic potential of protein kinase C inhibitors.

Authors:  D Bradshaw; C H Hill; J S Nixon; S E Wilkinson
Journal:  Agents Actions       Date:  1993-01

Review 8.  Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.

Authors:  Nikhil G Thaker; Ian F Pollack
Journal:  Expert Rev Neurother       Date:  2009-12       Impact factor: 4.618

9.  Involvement of protein kinase C in growth regulation of human meningioma cells.

Authors:  T Todo; R Fahlbusch
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

10.  Insulin-like growth factor (IGF)-I, -II and IGF-binding proteins in the cyst fluid of a patient with astrocytoma.

Authors:  W Zumkeller; M Sääf; T Rähn
Journal:  Childs Nerv Syst       Date:  1993-04       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.